PPAR-γLigand Inhibits Nasopharyngeal Carcinoma Cell Proliferation and Metastasis by Regulating E2F2

Author:

Yang Ping-Li1ORCID,Wang Jia-Shun1,Cheng Xiao-Mei2,Chen Jing-Cai1,Zhu Hui1,Li Xiao-Lan1,Cao Li1,Tang Wei1ORCID

Affiliation:

1. Department of Otorhinolaryngology, The First Affiliated Hospital, Shihezi University School of Medicine, Shihezi, Xinjiang, China

2. Outpatient Department of Xinjiang Production and Construction Corp, Urumchi, Xinjiang, China

Abstract

Purpose. Peroxisome proliferator-activated receptor-γ(PPAR-γ) is a nuclear hormone receptor with a key role in lipid metabolism. Previous studies have identified various roles of PPAR-γin cell cycle progression, cellular proliferation, and tumor progression. However, no report has described a role for PPAR-γin human nasopharyngeal carcinoma (NPC). Notably, some studies have reported a relationship between PPAR-γand E2F transcription factor 2 (E2F2), which has been identified as a regulator of cell cycle, apoptosis, and the DNA damage response. Notably, E2F2 has also been reported to correlate with a poor prognosis in patients with various malignancies.Methods. We used immunohistochemical (IHC) and western blot methods to evaluate PPAR-γand E2F2 expression and function in nonkeratinizing NPC and nasopharyngitis (NPG) tissue samples, as well as western blotting and CCK8 analyses in the NPC cell lines, CNE1 and CNE2.Results. We observed lower levels of PPAR-γexpression in nonkeratinizing NPC tissues compared with NPG tissues and determined an association between a low level of PPAR-γexpression with a more advanced tumor stage. Furthermore, strong E2F2 expression was detected in nonkeratinizing NPC tissues. We further demonstrated that rosiglitazone, a PPAR-γagonist, reduced E2F2 expression and proliferation in NPC cell lines.Conclusions. Our study results revealed a novel role for the PPAR-γ–E2F2 pathway in controlling NPC cell proliferation and metastasis.

Funder

First Affiliated Hospital of Shihezi University School of Medicine

Publisher

Hindawi Limited

Subject

Pharmacology (medical),Drug Discovery

Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3